16601427

Source:http://linkedlifedata.com/resource/pubmed/id/16601427

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0030705, umls-concept:C0045093, umls-concept:C0123931, umls-concept:C0282460, umls-concept:C0546837, umls-concept:C1519429
pubmed:issue	2
pubmed:dateCreated	2006-4-7
pubmed:abstractText	Metastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months. Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA04919, http://linkedlifedata.com/resource/pubmed/grant/CA11083, http://linkedlifedata.com/resource/pubmed/grant/CA12644, http://linkedlifedata.com/resource/pubmed/grant/CA27057, http://linkedlifedata.com/resource/pubmed/grant/CA32102, http://linkedlifedata.com/resource/pubmed/grant/CA35090, http://linkedlifedata.com/resource/pubmed/grant/CA35119, http://linkedlifedata.com/resource/pubmed/grant/CA35176, http://linkedlifedata.com/resource/pubmed/grant/CA35178, http://linkedlifedata.com/resource/pubmed/grant/CA35192, http://linkedlifedata.com/resource/pubmed/grant/CA35261, http://linkedlifedata.com/resource/pubmed/grant/CA35262, http://linkedlifedata.com/resource/pubmed/grant/CA35431, http://linkedlifedata.com/resource/pubmed/grant/CA38926, http://linkedlifedata.com/resource/pubmed/grant/CA42777, http://linkedlifedata.com/resource/pubmed/grant/CA45377, http://linkedlifedata.com/resource/pubmed/grant/CA45461, http://linkedlifedata.com/resource/pubmed/grant/CA45560, http://linkedlifedata.com/resource/pubmed/grant/CA45807, http://linkedlifedata.com/resource/pubmed/grant/CA45808, http://linkedlifedata.com/resource/pubmed/grant/CA46368, http://linkedlifedata.com/resource/pubmed/grant/CA46441, http://linkedlifedata.com/resource/pubmed/grant/CA52654, http://linkedlifedata.com/resource/pubmed/grant/CA58416, http://linkedlifedata.com/resource/pubmed/grant/CA58861, http://linkedlifedata.com/resource/pubmed/grant/CA63850, http://linkedlifedata.com/resource/pubmed/grant/CA67575, http://linkedlifedata.com/resource/pubmed/grant/CA76447, http://linkedlifedata.com/resource/pubmed/grant/CA86780
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8207754
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1537-453X
pubmed:author	pubmed-author:AbbruzzeseJames LJL, pubmed-author:AtkinsJames NJN, pubmed-author:BlankeCharles DCD, pubmed-author:DakhilShaker RSR, pubmed-author:GandaraDavid RDR, pubmed-author:McCoySheryl ASA, pubmed-author:ParadeloJorge CJC, pubmed-author:Southwest Oncology Group (SWOG), pubmed-author:WilliamsonStephen KSK, pubmed-author:YostKathleen JKJ
pubmed:issnType	Electronic
pubmed:volume	29
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	116-22
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:16601427-Adenocarcinoma, pubmed-meshheading:16601427-Adult, pubmed-meshheading:16601427-Aged, pubmed-meshheading:16601427-Aged, 80 and over, pubmed-meshheading:16601427-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16601427-Camptothecin, pubmed-meshheading:16601427-Carcinoma, Squamous Cell, pubmed-meshheading:16601427-Deoxycytidine, pubmed-meshheading:16601427-Disease Progression, pubmed-meshheading:16601427-Esophageal Neoplasms, pubmed-meshheading:16601427-Female, pubmed-meshheading:16601427-Humans, pubmed-meshheading:16601427-Infusions, Intravenous, pubmed-meshheading:16601427-Male, pubmed-meshheading:16601427-Middle Aged, pubmed-meshheading:16601427-Survival Analysis, pubmed-meshheading:16601427-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
pubmed:affiliation	University of Kansas Medical Center, Kansas City, KS, USA. swilliam@kumc.edu
pubmed:publicationType	Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural